Celgene Corporation (NASDAQ:CELG) has been assigned a $166.00 target price by analysts at Oppenheimer Holdings, Inc. in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s price objective would indicate a potential upside of 59.46% from the company’s previous close.
Several other equities research analysts also recently weighed in on CELG. Zacks Investment Research downgraded Celgene Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Robert W. Baird reissued an “outperform” rating and issued a $162.00 price objective on shares of Celgene Corporation in a report on Friday, July 21st. Mizuho set a $134.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 27th. Finally, Cowen and Company reissued an “outperform” rating and issued a $150.00 price objective on shares of Celgene Corporation in a report on Thursday, July 27th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $139.87.
Celgene Corporation (NASDAQ:CELG) opened at $104.10 on Thursday. The company has a market cap of $81,370.00, a P/E ratio of 15.45, a price-to-earnings-growth ratio of 0.76 and a beta of 1.79. Celgene Corporation has a one year low of $94.55 and a one year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.58 earnings per share. equities research analysts anticipate that Celgene Corporation will post 6.67 EPS for the current fiscal year.
WARNING: This piece was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://ledgergazette.com/2017/11/18/celgene-corporation-celg-pt-set-at-166-00-by-oppenheimer-holdings-inc.html.
In other news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the sale, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Insiders sold a total of 20,227 shares of company stock valued at $2,843,956 over the last quarter. Company insiders own 0.95% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Americafirst Capital Management LLC bought a new position in Celgene Corporation during the 3rd quarter worth $309,000. Belpointe Asset Management LLC bought a new position in Celgene Corporation during the 3rd quarter worth $844,000. Cetera Investment Advisers grew its stake in Celgene Corporation by 24.9% during the 3rd quarter. Cetera Investment Advisers now owns 2,736 shares of the biopharmaceutical company’s stock worth $398,000 after buying an additional 545 shares during the last quarter. Yellowstone Partners LLC bought a new position in Celgene Corporation during the 3rd quarter worth $751,000. Finally, Independent Advisor Alliance grew its stake in Celgene Corporation by 67.5% during the 3rd quarter. Independent Advisor Alliance now owns 7,262 shares of the biopharmaceutical company’s stock worth $1,031,000 after buying an additional 2,927 shares during the last quarter. Institutional investors and hedge funds own 79.16% of the company’s stock.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.